Opinions
The Panic-Proof Portfolio (Stockchase Research)
GenMark Diagnostics
GNMK-Q
PAST TOP PICK
Sep 01, 2020
$12.010
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Stockchase Research Editor: Michael O'Reilly This maker of COVID-19 test kits has just applied for Emergency Use Authorization of a new product that is better aligned to large batch testing. It can provide results for 96 samples in 5 hours. The stock has moved from $4 to over $20 since the pandemic outbreak. The recent pullback allows for an excellent entry level. We would trade this with a $13 stop-loss. Analysts at Needham increased the target to $22 (some 37% upside)-- the 5th such upgrade this year. Yield 0% (Analysts’ price target is $21.40)
biotechnology
pharmaceutical
Advertising
(A Top Pick Aug 18/20, Down 18.6%) We chose to be disciplined and recommend exiting position as the $13.00 stop-loss was triggered last week. This follows the announcement by Abbott Labs for their successful emergency use authorization antibody test ahead of the GNMK proposal.